Skip to main content

Advertisement

ADVERTISEMENT

News

News
08/17/2009
Patients with inflammatory bowel disease are more likely to have higher retinal drusen counts with longer disease duration and increased risk of complications, new study reports.
Patients with inflammatory bowel disease are more likely to have higher retinal drusen counts with longer disease duration and increased risk of complications, new study reports.
Patients with inflammatory bowel...
08/17/2009
Advances in Inflammatory Bowel Disease Network
News
08/17/2009
Patients with inflammatory bowel disease and a history of acute arterial events experienced lower rates of recurrent events when treated with anti-tumor necrosis factor agents and thiopurines.
Patients with inflammatory bowel disease and a history of acute arterial events experienced lower rates of recurrent events when treated with anti-tumor necrosis factor agents and thiopurines.
Patients with inflammatory bowel...
08/17/2009
Advances in Inflammatory Bowel Disease Network

Advertisement

Research Highlights
11/09/2001
Patients undergoing colectomy may benefit from enhanced kidney function monitoring, surveillance, and timely referral to nephrology care.
Patients undergoing colectomy may benefit from enhanced kidney function monitoring, surveillance, and timely referral to nephrology care.
Patients undergoing colectomy...
11/09/2001
Advances in Inflammatory Bowel Disease Network
News
09/19/2000
Switching from intravenous to subcutaneous infliximab was generally feasible, safe, and well-accepted, leading to a low risk of relapse in most patients with inflammatory bowel disease, a new study indicates.
Switching from intravenous to subcutaneous infliximab was generally feasible, safe, and well-accepted, leading to a low risk of relapse in most patients with inflammatory bowel disease, a new study indicates.
Switching from intravenous to...
09/19/2000
Advances in Inflammatory Bowel Disease Network
News
02/14/2000
Researchers aimed to study the efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy among patients with moderately to severely active ulcerative colitis.
Researchers aimed to study the efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy among patients with moderately to severely active ulcerative colitis.
Researchers aimed to study the...
02/14/2000
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement